N/A
N=24
PINPOINT: Gaming Technology for SCD Pain
Sickle Cell Disease · Sickle Cell Anemia in Children · Sickle Cell Thalassemia · Sickle Cell SC Disease
Bottom Line
View on ClinicalTrials.gov: NCT04579926 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Sickle Cell Self-efficacy Scale Reported by Adolescents — 34.6 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pinpoint app (Other)
- Age
- Pediatric · 13+ yrs
- Sex
- All
- Sponsor
- Klein Buendel, Inc.
- Primary completion
- Jun 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sickle Cell Self-efficacy Scale Reported by Adolescents |
38.9 | — |
| PRIMARY Sickle Cell Self-efficacy Scale Reported by Adolescents |
38.9 | — |
| PRIMARY Sickle Cell Self-efficacy Scale Reported by Adolescents |
38.9 | — |
| PRIMARY Sickle Cell Self-efficacy Scale Reported by Adolescents |
38.9 | — |
| PRIMARY Sickle Cell Self-efficacy Scale |
39.0 | — |
| SECONDARY System Usability Scale (SUS) |
72.5 | — |
Summary
Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet programs to assist SCD adolescents with better identification and communication about pain are lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve self-care. Pinpoint is an interactive gaming app that will be tested in a Phase II project to determine whether the app assists SCD teens with improving their communication and identification skills for pain self-report.
Eligibility Criteria
Inclusion Criteria
- Be 13-17 years of age
- Be diagnosed with sickle cell disease
- Able to read and speak English
- Able to assent to participate
Exclusion Criteria
- Not 13-17 years of age
- Not diagnosed with sickle cell disease
- Unable to read and speak English
- Unable to assent to participate
Data sourced from ClinicalTrials.gov (NCT04579926). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.